Over the past years, eosinophils have become a focus of scientific interest, especially in the context of their recently uncovered functions (e.g. antiviral, anti-inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological and pathological conditions. Eosinophils are involved in the pathogenesis of many diseases which can be classified into primary (clonal) and secondary (reactive) disorders and idiopathic (hyper)eosinophilic syndromes. Depending on the biological specimen, the eosinophil count in different body compartments may serve as a biomarker reflecting the underlying pathophysiology and/or activity of distinct diseases and as a therapy-driving (predictive) and monitoring tool. Personalized selection of an appropriate therapeutic strategy directly or indirectly targeting the increased number and/or activity of eosinophils should be based on the understanding of eosinophil homeostasis including their interactions with other immune and non-immune cells within different body compartments. Hence, restoring as well as maintaining homeostasis within an individual's eosinophil pool is a goal of both specific and non-specific eosinophil-targeting therapies. Despite the overall favourable safety profile of the currently available anti-eosinophil biologics, the effect of eosinophil depletion should be monitored from the perspective of possible unwanted consequences.

Amsterdam UMC Location University of Amsterdam Pulmonary Diseases Amsterdam The Netherlands

Center for Environmental Medicine Asthma and Lung Biology Department of Paediatrics University of North Carolina Chapel Hill North Carolina USA

Child Life and Health and Centre for Inflammation Research The Queen's Medical Research Institute University of Edinburgh Edinburgh UK

Department Center of Translational Immunology University Medical Center Utrecht Utrecht The Netherlands

Department Dermatology Allergology University Medical Center Utrecht Utrecht The Netherlands

Department Microbiology Immunology and Transplantation KU Leuven Catholic University of Leuven Leuven Belgium

Department of Clinical and Transplant Immunology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Clinical Immunology and Allergology University Teaching Hospital in Martin Martin Slovak Republic

Department of Clinical Sciences Lund Respiratory Medicine Allergology and Palliative Medicine Lund University Lund Sweden

Department of Dermatology Inselspital Bern University Hospital University of Bern Bern Switzerland

Department of Immunology 2nd Faculty of Medicine Charles University Motol University Hospital Prague Czech Republic

Department of Medicine McMaster University Hamilton Ontario Canada

Department of Medicine University of Alberta Edmonton Alberta Canada

Department of Paediatrics Jessenius Faculty of Medicine in Martin Comenius University in Bratislava University Teaching Hospital in Martin Martin Slovak Republic

Department of Pathophysiology Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovak Republic

Department of Pulmonology and Phthisiology Jessenius Faculty of Medicine in Martin Comenius University in Bratislava University Teaching Hospital in Martin Martin Slovak Republic

Department of Respiratory Medicine 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department Pulmonary Diseases University Medical Center Utrecht Utrecht The Netherlands

Institute of Biochemistry Brandenburg Medical School Neuruppin Germany

Institute of Pathophysiology and Allergy Research Center for Pathophysiology Infectiology and Immunology Medical University of Vienna Vienna Austria

Institute of Pharmacology University of Bern Bern Switzerland

Laboratory of Clinical Immunology Department of Microbiology and Immunology KU Leuven Leuven Belgium

Outpatient Clinic for Clinical Immunology and Allergology Nitra Slovak Republic

The Firestone Institute for Respiratory Health Research Institute of St Joe's Hamilton Hamilton Ontario Canada

Zobrazit více v PubMed

Blanchard C, Rothenberg ME. Biology of eosinophils. Adv Immunol. 2009;101:81-121.

Chusid MJ. Eosinophils: friends of foes? J Allergy Clin Immunol Pract. 2018;6:1439-1444.

Hillas G, Fouku E, Papaioannou A. Antibodies targeting the interleukin-5 signalling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020;14(4):353-365.

Simon D, Simon HU. Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019;46:29-33.

Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med. 2017;4:101.

Abdala-Valencia H, Coden ME, Chiarella SE, et al. Shaping eosinophils identity in the tissue contexts of development, homeostasis, and disease. J Leucoc Biol. 2018;104(1):95-108.

Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835-1851.

Breiteneder H, Peng YQ, Agache I, et al. Biomarkerdss for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039-3068.

Heaney LG, Busby J, Hanratty CE, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2021;9(1):P57-P68.

Striz I, Golebski K, Strizova Z, et al. New insight into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023;137(9):727-753.

Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15:179-209.

Ehrlich P. Beitrage zur Kenntnis der granulirten Bindegewbszellen und der ecosinophilen Leukocythen. Archiv fur Anatomie und Physiologie, Physiologische Abteilung. 1879;3:166-169.

Gauvreau GM, Denburg JA. Human mast cell and basophil/eosinophil progenitors. Methods Mol Biol. 2015;1220:59-68.

Hassani M, Tak T, van Aalst C, et al. Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma. iScience. 2021;24(8):102913.

Geijsen N, Koenderman L, Coffer PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev. 2001;12:19-25.

Johnston LK, Hsu CL, Krier-Burris RA, et al. IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis. J Immunol. 2016;197:3445-3453.

Mack EA, Pear WS. Transcription factor and cytokine regulation of eosinophil lineage commitment. Curr Opin Hematol. 2020;27:27-33.

Hartl S, Breyer MK, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020;55(5):1901874.

Dorman SC, Efthimiadis A, Babirad I, et al. Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis. Am J Respir Crit Care Med. 2004;169(5):573-577.

Steinbach KH, Schick P, Trepel F, et al. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut. 1979;39(1):27-38.

Walle AJ, Parwaresch MR. Estimation of effective eosinopoiesis and bone marrow eosinophil reserve capacity in normal man. Cell Tissue Kinet. 1979;12(3):249-255.

Willebrand R, Voehringer D. Regulation of eosinophil development and survival. Curr Opin Hematol. 2017;24(1):9-15.

Rodrigo-Munoz JM, Gil-Martinez M, Sastre B, del Pozo V. Emerging evidence for pleiotropism of eosinophils. Int J Mol Sci. 2021;22(13):7075.

Shah K, Ignacio A, McCoy KD, Harris NL. The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol. 2020;13(4):574-583.

Koenderman L. Priming: a critical step in the control of eosinophil activation. In: Lee JJ, Rosenberg HF, eds. Eosinophils in Health and Disease. Academic Press, Elsevier; 2013:170-178. ISBN 978-012-394385-9.

Takatsu K, Tominaga A. Interleukin 5 and its receptor. Prog Growth Factor Res. 1991;3(2):87-102.

Nishinakamura R, Miyajima A, Mee PJ, Tybulewicz VL, Murray R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood. 1996;88(7):2458-2464.

Conus S, Straumann A, Bettler E, Simon HU. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol. 2010;126(1):175-177.

Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144-2148.

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleuin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199-204.

Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279-3295.

Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol. 2002;169(11):6452-6458.

Gigon L, Fettrelet T, Yousefi S, Simon D, Simon HU. Eosinophils from A to Z. Allergy. 2023;78(7):1810-1846.

O'Connell EM, Nutman TB. Eosinophilia in infectious diseases. Immunol Allergy Clin North Am. 2015;35(3):493-522.

Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113(1):30-37.

Bochner BS. The eosinophil: for better or worse, in sickness and in health. Ann Allergy Asthma Immunol. 2019;121(2):150-155.

Jackson DJ, Akuthota P, Roufosse F. Eosinophils and eosinophilic immune dysfunction in health and disease. Eur Respir Rev. 2022;31(163):210150.

Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279-1291.

Lee MW, Odegaard JI, Mukundan L, et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell. 2015;160(1-2):74-87.

Da Silva FR, Soares Thimoteo D, Ferraz Carbonel A, et al. Histomorphometric analysis of the endometrium in an ectopic model of endometriosis in mice. Gynecol Endocrinol. 2022;38:874-878.

Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563-575.

Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol. 1994;94(3 Pt 1):427-438.

Knol EF, Tackey F, Tedder TF, et al. Comparison of human eosinophil and neutrophil adhesion to endothelial cells under nonstatic conditions. Role of L-selectin. J Immunol. 1994;153(5):2161-2167.

Monteiro RC, Hostoffer RW, Cooper MD, Bonner JR, Gartland GL, Kubagawa H. Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest. 1993;92(4):1681-1685.

Koenderman L, Hermans SW, Capel PJ, van de Winkel JG. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG fc receptor, hFc gamma RII, on human eosinophils. Blood. 1993;81(9):2413-2419.

Yoon J, Ponikau JU, Lawrence CB, Kita H. Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. J Immunol. 2008;181(4):2907-2915.

Koenderman L, van der Bruggen T, Schweizer RC, et al. Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Eur Respir J. 1996;22:119s-125s.

Bracke M, van de Graaf E, Lammers JW, Coffer PJ, Koenderman L. In vivo priming of FcalphaR functioning on eosinophils of allergic asthmatics. J Leukoc Biol. 2000;68(5):655-661.

Lacy P, Abdel-Latif D, Steward M, Musat-Marcu S, Man SFP, Moqbel R. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol. 2003;170(5):2670-2679.

Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709-750.

Mukherjee M, Lacy P, Ueki S. Eosinophil extracellular traps and inflammatory pathologies - untangling the web! Front Immunol. 2018;9:2763.

Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2-3):135-143.

Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol. 2014;5:570.

Tool AT, Koenderman L, Kok PT, Blom M, Roos D, Verhoeven AJ. Release of platelet-activating factor is important for the respiratory burst induced in human eosinophils by opsonized particles. Blood. 1992;79(10):2729-2732.

Lacy P, Logan MR, Bablitz B, Moqbel R. Fusion protein vesicle-associated membrane protein 2 is implicated in IFN-gamma-induced piecemeal degranulation in human eosinophils from atopic individuals. J Allergy Clin Immunol. 2001;107(4):671-678.

Lacy P. The role of rho GTPases and SNAREs in mediator release from granulocytes. Pharmacol Ther. 2005;107(3):358-376.

Logan MR, Lacy P, Bablitz B, Moqbel R. Expression of eosinophil target SNAREs as potential cognate receptors for vesicle-associated membrane protein-2 in exocytosis. J Allergy Clin Immunol. 2002;109(2):299-306.

Logan MR, Lacy P, Odemuyiwa SO, et al. A critical role for vesicle-associated membrane protein-7 in exocytosis from human eosinophils and neutrophils. Allergy. 2006;61(6):777-784.

Willetts L, Felix LC, Jacobsen E, et al. Vesicle-associated membrane protein 7-mediated eosinophil degranulation promotes allergic airway inflammation in mice. Commun Biol. 2018;1:83.

Radonjic-Hoesli S, Wang X, de Graauw E, et al. Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signalling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol. 2017;140(6):1632-1642.

Simon HU, Yousefi S, Germic N, et al. The cellular functions of eosinophils: collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(1):11-23.

Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defence. Nat Med. 2008;14(9):949-953.

Nogawa H, Suzuki H, Kawabata Y, et al. An unusual case of eosinophilic lung disease with multiple cyst formation. Respir Med Case Rep. 2020;31:101300.

Fettrelet T, Gigon L, Karaulov A, Yousefi S, Simon HU. The enigma of eosinophil degranulation. Int J Mol Sci. 2021;22(13):7091.

Ueki S, Konno Y, Takeda M, et al. Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes. J Allergy Clin Immunol. 2016;137(1):258-267.

Ueki S, Miyabe Y, Yamamoto Y, et al. Charcot-Leyden crystals in eosinophilic inflammation: active cytolysis leads to crystal formation. Curr Allergy Asthma Rep. 2019;19(8):35.

Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;364(6442):eaaw4295.

Sabogal Piñeros YS, Bal SM, Dijkhuis A, et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898-1909.

Rodrigo-Munoz JM, Sastre B, Canas JA, et al. Eosinophil response against classic and emerging respiratory viruses: COVID-19. J Investig Allergol Clin Immunol. 2021;31:94-107.

Flores-Torres AS, Salinas-Carmona MC, Salinas E, Rosas-Taraco AG. Eosinophils and respiratory viruses. Viral Immunol. 2019;32(5):198-307.

LeMessurier KS, Tiwary M, Morin NP, Samarasinghe AE. Respiratory barrier as a safeguard and regulator of defense against influenza A virus and Streptococcus pneumoniae. Front Immunol. 2020;11:3.

Jesenak M, Banovcin P, Diamant Z. COVID-19, chronic inflammatory respiratory diseases and eosinophils - observation from reported clinical case series. Allergy. 2020;75(7):1819-1822.

Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. Int J Lab Hematol. 2021;43(Suppl. 1):137-141.

Myari A, Papapetrou E, Tsaousi C. Diagnostic value of white blood cell parameters for COVID-19: is there a role for HFLC and IG? Int J Lab Hematol. 2022;44(1):104-111.

Cazzaniga M, Fumagalli LAM, D'angelo L, et al. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int J Clin Pract. 2021;75:e14047.

Eijmael M, Janssens N, le Cessie S, van Dooren Y, Koster T, Karim F. Coronavirus disease 2019 and peripheral blood eosinophil counts: a retrospective study. Infection. 2021;49:1325-1329.

Zein JG, Strauss R, Attaway AH, et al. Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroid-treated patients. J Allergy Clin Immunol Pract. 2022;10:742-750.

Eger K, Hashimoto S, Braunstahl GJ, et al. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respir Med. 2020;177:106287.

Francis CHR, Hearn AP, Ratnakumar S, et al. Covid-19 in the absence of eosinophils: the outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab. Allergy. 2022;77(8):2558-2560.

Huang L, Appleton JA. Eosinophils in helminth infection: defenders and dupes. Trends Parasitol. 2016;32:798-807.

Cadman E, Thysse KA, Bearder S, et al. Eosinophils are important for protection, immunoregulation and pathology during infection with nematode microfilariae. PLoS Pathog. 2014;10:e1003988.

Ondari E, Calvino-Sanles E, First NJ, Gestal MC. Eosinophils and bacteria, the beginning of a story. Int J Mol Sci. 2021;22(15):8004.

Linch SN, Gold JA. The role of eosinophils in non-parasitic infections. Endocri Metab Immune Disord Drug Targets. 2011;11:165-172.

Morshed M, Yousefi S, Stockle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67:1127-1137.

Figueiredo RT, Neves JS. Eosinophils in fungaldiseases: an overview. J Leukoc Biol. 2018;104:49-60.

Austen KF. Homeostasis of effector systems which can also be recruited for immunologic reactions. J Immunol. 1978;121(3):793-805.

Lingblom C, Andersson J, Andersson K, Wennerås C. Regulatory eosinophils suppress T cells partly through Galectin-10. J Immunol. 2017;198(12):4672-4681.

Takemura N, Kurashima Y, Mori Y, et al. Eosinophil depletion suppresses radiation-induced small intestinal fibrosis. Sci Transl Med. 2018;10(429):eaan0333.

Siddiqui S, Bachert C, Bjermer L, et al. Eosinophils and tissue remodeling: relevance to airway disease. J Allergy Clin Immunol. 2023;S0091-6749(23)00800-X. doi:10.1016/j.jaci.2023.06.005

Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332(6026):243-247.

Brigger D, Riether C, van Brummelen R, et al. Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. Nat Metab. 2020;2(8):688-702.

Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594-607.

Hu G, Wang S, Zhong K, et al. Tumor-associated tissue eosinophilia predicts favourable clinical outcome in solid tumors: a meta-analysis. BMC Cancer. 2020;20:454.

Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119(6):1291-1300. Erratum in: J Allergy Clin Immunol. 2007;120(3):515.

Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68(5):823-833.

Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243-1259.

Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157-176.

Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78:47-59.

Wang SA. The diagnostic work-up of hypereosinophilia. Pathobiology. 2019;86(1):39-52.

Radonjic-Hoesli S, Martignoni Z, Cazzaniga S, et al. Characteristics of dermatological patients with blood eosinophilia: A retrospective analysis of 453 patients. J Allergy Clin Immunol Pract. 2022;10(5):1229-1237.e8.

Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy. 2019;9:36.

Weller PF, Klion AD. Approach to the patient with unexplained eosinophilia. 2022.

Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72-80.

Jeffery P, Holgate S, Wenzel S, Endobronchial Biopsy Workshop. Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. Am J Respir Crit Care Med. 2003;168(6 Pt 2):S1-S17.

Diamant Z, Boot JD, Mantzouranis E, Flohr R, Sterk PJ, Gerth van Wijk R. Biomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther. 2010;23(6):468-481.

Rakowski E, Zhao S, Liu M, et al. Variability of blood eosinophils in patients in a clinic for severe asthma. Clin Exp Allergy. 2019;49(2):163-170.

Grootendorst DC, Sont JK, Willems LN, et al. Comparison of inflammatory cell counts in asthma: induced sputum vs. bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy. 1997;27(7):769-779.

Koenderman L, Hassani M, Mukherjee M, Nair P. Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter? Allergy. 2021;76(4):1294-1297.

Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med. 2015;3(11):824-825.

Felarca AB, Lowell FC. The total eosinophil count in a nonatopic population. J Allergy. 1967;40(1):16-20.

Schwartz JT, Fulkerson PC. An approach to the evaluation of persistent hypereosinophilia in pediatric patients. Front Immunol. 2018;9:1944.

Dahl R, Venge P, Olsson I. Blood eosinophil leucocytes and eosinophil cationic protein. Diurnal variation in normal subjects and patients with bronchial asthma. Scand J Respir Dis. 1978;59:323-325.

Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013;502:245-248.

Gibson PG. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirology. 2018;23:12-13.

Ullmann N, Bossley CJ, Fleming L, Silvestri M, Bush A, Saglani S. Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy. 2013;68:402-406.

Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509-1518.

Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115-120.

Lim HF, Nair P. Airway inflammation and inflammatory biomarkers. Semin Respir Crit Care Med. 2018;39:56-63.

Hilvering B, Koenderman L. Quality over quantity: eosinophilactivation status will deepen the insight into eosinophilic diseases. Respir Med. 2023;207:107094.

Lombardi C, Bert A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42-53.

Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804-813.

Pizzichini E, Pizzichini M, Efthimiadis A, Hargreave F, Dolovich J. Measurement of inflammatory indices in indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9:1174-1180.

Dasgupta A, Zhang S, Thabane L, Nair P. Sample size for clinical trials using sputum eosinophils as a primary outcome. Eur Respir J. 2013;42:1003-1011.

Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophils counts: a randomised controlled trial. Lancet. 2002;360(9347):1715-1721.

Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997;155(5):1501-1508.

Wang G, Baines KJ, Fu JJ, et al. Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma. Eur Respir J. 2016;47(4):1123-1133.

Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27(3):483-494.

Seys SF. Role of sputum biomarkers in the management of asthma. Curr Opin Pulm Med. 2017;23(1):34-40.

Gomez JL, Chen A, Diaz MP, et al. A network of sputum microRNAs is associated with neutrophilic airway inflammation in asthma. Am J Respir Crit Care Med. 2020;202(1):51-64.

Schoenfield JPR, Burg D, Nicholas B, et al. Stratification of asthma phenotypes by airway proteomic signatures. J Allergy Clin Immunol. 2019;144(1):70-82.

Seys SF, Scheers H, van den Brande P, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Resp Res. 2017;18(1):39.

Van Rensen ELJ, Hiemstra PS, Rabe KF, Sterk PJ. Assessment of microvascular leakage via sputum induction: the role of substance P and neurokinin A in patients with asthma. Am J Respir Crit Care Med. 2002;165(9):1275-1279.

Zuiker RHJA, Tribouley C, Diamant Z, et al. Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test. Eur Clin Respir J. 2016;3:31324.

Zuiker RGJA, Ruddy MK, Morelli N, et al. Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. Eur Clin Respir J. 2015;2:28319.

Lay JC, Peden DB, Alexis NE. Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways. Inhal Toxicol. 2011;23(7):392-406.

Vidal S, Bellido-Casado J, Granel C, Crespo A, Plaza V, Juarez C. Flow cytometry analysis of leukocytes in induced sputum from asthmatic patients. Immunobiology. 2012;217(7):692-697.

Abdel-Aziz MI, Vijverberg SJH, Neerincx AH, et al. A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. Eur Respir J. 2022;59(1):210603.

Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: associations with disease feature and severity. J Allergy Clin Immunol. 2015;136(4):874-884.

Chami HA, Diaz-Mendoza J, Chua A, et al. Transbronchial biopsy and cryobiopsy in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease. Ann Am Thorac Soc. 2021;18(1):148-161.

Cottin V. Eosinophilic lung diseases. Clin Chest Med. 2016;37(3):535-556.

De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute eosinophilic pneumonia. Causes, diagnosis, and management. Am J Respir Crit Care Med. 2018;197(6):728-736.

Hetzel J, Eberhardt R, Herth FJF, et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J. 2012;39(3):685-690.

Rosenberg CE, Khoury P. Approach to eosinophilia presenting with pulmonary symptoms. Chest. 2021;159(2):507-516.

Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotype. J Allergy Clin Immunol. 2014;133(4):997-1007.

Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394.

Seys SF, Grabowski M, Adriaensen W, et al. Sputum cytokine mapping revealts an ‘IL-5, IL-17A, IL-25-high’ pattern associated with poorly controlled asthma. Clin Exp Allergy. 2013;43(9):1009-1017.

Henderson AG, Andreson WH, Ceppe A, et al. Mucus hydration in subjects with stable chronic bronchitis: a comparison of spontaneous and induced sputum. COPD. 2018;15(6):572-580.

Holz O, Seiler T, Karmeier A, et al. Assessing airway inflammation in clinical practice - experience with spontaneous sputum analysis. BMC Pulm Med. 2008;8:5.

Pizzichini MM, Popov TA, Efthimiadis A, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154(4 Pt 1):866-869.

Bakakos P, Schleich F, Alchanatis M, Louis R. Induced sputum in asthma: from bench to bedside. Curr Med Chem. 2011;18(10):1415-1422.

Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154(2 Pt 1):308-317.

Green R, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875-879.

Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax. 1997;52(6):498-501.

De Corso E, Lucidi D, Battista M, et al. Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol. 2017;7(9):861-867.

Miman MC, Uzun O, Gurses I, Kuku I, Ozturan O, Akarcay M. The sensitivity of nasal eosinophilia in allergic rhinitis. Eur Arch Otorhinolaryngol. 2007;264(9):1013-1018.

Zhu Z, Wang W, Zhang X, et al. Nasal fluid cytology and cytokine profiles of eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Rhinology. 2020;58(4):314-322.

Howarth PH, Persson CG, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol. 2005;115(3 Suppl 1):S414-S441.

Siddiqui S, Wenzel SE, Bozik ME, et al. Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;S0091-6749(23)00709-1. doi:10.1016/j.jaci.2023.05.014

Amorim MM, Araruna A, Caetano LB, Cruz AC, Santoro LL, Fernandes AL. Nasal eosinophilia: an indicator of eosinophilic inflammation in asthma. Clin Exp Allergy. 2010;40(6):867-874.

Amorim MM, Fernandes PBL, Caetano LB, Dracoulakis S, Santoro IL, Fernandes ALG. Nasal lavage is better than blood count in predicting sputum eosinophilia. Clin Exp Allergy. 2015;45(5):1006-1008.

Radonjic-Hoesli S, Brüggen MC, Feldmeyer L, Simon HU, Simon D. Eosinophils in skin diseases. Semin Immunopathol. 2021;43(3):393-409.

Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller AS, Leffell D. Fitzpatrick's Dermatology in General Medicine. 8th ed. McGraw-Hill; 2011.

Martin LB, Kita H, Leiferma KM, Gleich GJ. Eosinophils in allergy: role in disease, degranulation and cytokines. Int Arch Allergy Immunol. 1996;109(3):207-215.

Leiferman KM, Peters MS. Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract. 2018;6(5):1462-1482.e6.

Long H, Zhang G, Wang L, Lu Q. Eosinophilic skin diseases: A comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):189-213.

Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol. 2000;136(6):717-721.

Graeff-Teixeira C, da Silva AC, Yoshimura K. Update on eosinophilic meningoencephalitis and its clinical relevance. Clin Microbiol Rev. 2009;22(2):322-348.

Fulkerson DH, Boaz JC. Cerebrospinal fluid eosinophilia in children with ventricular shunts. J Neurosurg Pediatr. 2008;1(4):288-295.

Heidemann SM, Fiore M, Sood S, Ham S. Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction. Pediatr Neurosurg. 2010;46(4):255-258.

Salafia CM, Popek EJ. Inflammatory and vascular placental pathology. Glob Libr Women's Med. 2009. doi:10.3843/glowm.10152

Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2007;101:696-705.

Schmekel B, Ahlner J, Malmstrom M, Venge P. Eosinophil cationic protein (ECP) in saliva: a new marker of disease activity in bronchial asthma. Respir Med. 2001;95(8):670-675.

Prehn A, Seger RA, Torresani T, Molinari L, Sennhauser FH. Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood. Pediatr Allergy Immunol. 2000;11:87-94.

Munthe-Kaas MC, Gerritsen J, Carlsen KH, et al. Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy. 2007;62(4):429-436.

Jonsson UB, Bystrom J, Stalenheim G, Venge P. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy. 2002;32(7):1092-1095.

Noguchi E, Iwama A, Takeda K, et al. The promoter polymorphism in the eosinophil cationic protein gene and its influence on the serum cationic protein level. Am J Respir Crit Care Med. 2003;167(2):180-184.

Nair P, Ochkur SI, Protheroe C, et al. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy. 2013;68(9):1177-1184.

Venge P. Monitoring the allergic inflammation. Allergy. 2004;59(1):26-32.

Kristjánsson S, Strannegård IL, Strannegård Q, Peterson C, Enander I, Wennergren G. Urinary eosinophil protein X in children with atopic asthma: a useful marker of anti-inflammatory treatment. J Allergy Clin Immunol. 1996;97:1179-1187.

Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma. 2010;47(5):568-573.

Oymar K. High levels of urinary eosinophil protein X in young asthmatic children predict persistent atopic asthma. Pediatr Allergy Immunol. 2001;12:312-317.

Ochkur SI, Kim JD, Protheroe CA, et al. A sensitive high throughput ELISA for human eosinophil peroxidase: a specific assay to quantify eosinophil degranulation from patient-derived sources. J Immunol Methods. 2012;384(1-2):10-20.

Rank MA, Ochkur SI, Lewis JC, et al. Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia. Allergy. 2016;71(4):567-570.

Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014;289(25):17406-17415.

Johansson MW. Eosinophil activation status in separate compartments and association with asthma. Front Med (Lausanne). 2017;4:75.

Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22-37.

Khatri SB, Iaccarino JM, Barochia A, et al. American Thoracic Society assembly on allergy, immunology and inflammation. Am J Respir Crit Care Med. 2021;204(10):e97-e109.

Banovcin P, Jesenak M, Michnova Z, et al. Factors attributable to the level of exhaled nitric oxide in asthmatic children. Eur J Med Res. 2009;14(Suppl 4):9-13.

Alving K, Diamant Z, Lucas S, et al. Point-of-care biomarkers in asthma management: tome to move forward. Allergy. 2020;75(4):995-997.

Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014;108(6):830-841.

Dweik RD, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615.

Izumo T, Tone M, Kuse N, et al. Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study. Ann Transl Med. 2020;8(7):438.

Maglio A, Vitale C, Pellegrino S, et al. Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma. Biomedicine. 2021;9(11):1550.

Crespo A, Giner J, Torrejon M, et al. Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum. J Asthma. 2016;53:459-464.

Gao J, Wu F. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy Asthma Clin Immunol. 2018;14:21.

Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancer Respir Med. 2015;3(4):290-300.

Couillard S, Laugerud A, Jabeen M, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022;77(2):199-202.

Menzies-Gow A, Mansur AH, Brughtling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.

Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23(7):650-666.

Della Valle L, Gatta A, Farinelli A, et al. Allergooncology: an expanding research area. J Biol Regul Homeost Agents. 2020;34:319-326.

Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609-617.

Zaynagetdinov R, Sherrill TP, Gleaves LA, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75:1624-1634.

Jacquelot N, Seillet C, Wang M, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851-864.

Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633-656.

Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008;119:199-206.

Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-1214.

Simon HU, Klion A. Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol. 2012;49:160-170.

Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PGGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007;110(10):3552-3556.

Gleixner KV, Peter B, Blatt K, et al. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013;98(9):1450-1457.

Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276-293.

St. Germain O, Lachapelle P, Pavord ID, Couillard S. Tackling “people remodelling” in corticosteroid-dependent asthma with Type-2 targeting biologics and a formal corticosteroid weaning protocol. touchREVIEWS Respir Pulm Dis. 2022;7:44-47.

Belvisi MG. Regulation of inflammatory cell function by corticosteroids. Proc Am Thorac Soc. 2004;1:207-214.

Ortega H, Llanos JP, Lafeuille MH, et al. Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. J Asthma. 2019;56(8):808-815.

Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol. 1994;94(6):P1202-P1213.

Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J. 2014;7(1):32.

Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141.

Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-984.

Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985-993.

Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-995.

Buttgereit T, Bonnekoh H, Church MK, Bergmann KC, Siebenhaar F, Metz M. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. J Dtsch Dermatol Ges. 2019;17(11):1171-1172.

Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336-1346.

Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349(24):2334-2339.

Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-1228.

Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693-696.

Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21-30.

Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669-672.

Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132.

Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.

Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):CD010834.

Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines - recommendations for severe asthma. Allergy. 2021;76(1):14-44.

Golebski K, Dankelman LHM, Bjorkander S, et al. Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy. ERH Open Res. 2021;7(4):00381-2021.

Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-1141.

Gibson PG, Prazma CM, Chupp GL, et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Med. 2021;22(1):171.

Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141-1153.

Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definition and management. J Allergy Clin Immunol. 2021;147(1):29-36.

Fokkens WJ, Lund VJ, Hopkins C, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020;58(2):82-111.

Hellings PW, Fokkens WJ, Orlandi R, et al. The EUFOREA pocket guide for chronic rhinosinusitis. Rhinology. 2023;61:85-89.

Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021;59(1):2102730.

Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116.e1.

Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.

Boyle JV, Lam K, Han JK. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis. Immunotherapy. 2020;12(2):111-121.

Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111(4):714-719.

Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med. 2017;196(11):1385-1395.

Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75-86.e8.

Mukherjee M, Forero DF, Tran S, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020;56(4):2000117.

McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021;9(10):1174-1184.

Pavord ID, Buhl R, Kraft M, et al. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Res. 2022;8(2):00560-2021.

Barretto KT, Brockman-Schneider RA, Kuipers I, et al. Human airway epithelial cells express functional IL-5 receptor. Allergy. 2020;75(8):2127-2130.

Buchheit KM, Laidlaw TM, Levy JM. Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):348-350.

Levy BD, Noel PJ, Freemer MM, et al. Future research directions in asthma. An NHLBI working group report. Am J Respir Crit Care Med. 2015;192(11):1366-1372.

Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other? Nat Rev Immunol. 2021;21(11):739-751.

Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68(7):829-835.

Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of Mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058-2070.

Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of Reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572-1581.

Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461-467.

Jacobsen EA, Jackson DJ, Heffler E, et al. Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies. Annu Rev Immunol. 2021;39:719-757.

Jackson DJ, Pavord ID. Living without eosinophils: evidence from mouse and man. Eur Respir J. 2023;61(1):2201217.

Wechsler ME, Ackerman SJ, Weller PF. In reply - are eosinophils needed for normal health? Mayo Clin Proc. 2022;97(4):805-807.

Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336-1342.

Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.e7.

Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344-1353.

Mathur SK, Modena BD, Coumou H, Barker P, Kreindler JL, Zangrilli JG. Postbronchodilator lung function improvements with Benralizumab for patients with severe asthma. Allergy. 2020;75(3):669-672.

Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458.

Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568-576.

Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086-1096.

Lommatzsch M, Marchewski H, Schwefel G, Stoll P, Virchow JC, Bratke K. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin Exp Allergy. 2020;50(11):1267-1269.

Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529-1532.

Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21-29.

Poznanski S, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021;76(1):375-379.

Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023-1034.

Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):P158-P170.

Singh D, Bafadhel M, Brightling CE, et al. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202(5):660-671.

Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46-59.

Geng B, Bachert C, Busse WW, et al. Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies. J Allergy Clin Immunol Pract. 2022;10(3):732-741.

Kuo CHS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49(2):1602135.

Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.

Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.

Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483-1492.

Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583-593.

Van Neerven RJJ, Knol EF, Ejrnaes A, Wurtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol. 2006;141(2):119-129.

Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma. Am J Respir Crit Care Med. 2013;187(8):804-811.

Mukherjee M, Kjasgaard M, Radford K, et al. Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy Asthma Clin Immunol. 2019;15:21.

Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716-1726.

Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602-609.

Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double-blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990-998.

Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr. 2011;170(11):1471-1474.

Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120(3):594-601.

Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197-207.

Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593-610.

Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.

Trischler J, Bottoli I, Janocha R, et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clin Transl Immunol. 2021;10(3):e1255.

Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381:1321-1332.

Domingo C, Maspero JF, Castro M, et al. Dupilumab efficacy in steroid-dependent severe asthma by baseline oral corticosteroid dose. J Allergy Clin Immunol Pract. 2022;10(7):1835-1843.

Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11-25.

Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139.

Silverberg JI, Rubini NPM, Pires MC, et al. Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2022;10(5):1279-1285.e1.

Fujieda S, Matsune S, Takeno S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2022;77(1):186-196.

Wechsler M, Klion A, Paggiaro P, et al. Effect of dupilumab treatment on blood eosinophil levels in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), or atopic dermatitis (AD). J Allergy Clin Immunol. 2021;147(2):AB140.

Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(1):171-177.

Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a phase 2 randomized Trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122.e10.

Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol. 1995;154(2):799-803.

Dubois GR, Schweizer RC, Versluis C, Bruijnzeel-Koomen CA, Bruijnzeel PL. Human eosinophils constitutively express a functional interleukin-4-induced priming of chemotactic responses and induction of PI-3 kinase activity. Am J Respir Cell Mol Biol. 1998;19(4):691-699.

Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.

Olaguibel JM, Sastre J, Rodriguez JM, Del Pozo V. Eosinophilia induced by blocking the IL-4/IL-13 pathway: potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022;32(3):165-180.

Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy. 2021;76(9):2920-2923.

Marcant P, Balaye P, Mehri R, et al. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2021;35(6):e394-e396.

Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120-1135.

Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248-1249.

Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on bloode osinophil counts in patients with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10:2695-2709.

Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16:713-721.

https://ginasthma.org

Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):368-373.

Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013;13(3):287-291.

Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013-1021.

Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946.

Emson C, Diver S, Chachi L, et al. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Tezepelumab on airway inflammation in patients with uncontrolled asthma. Respir Med. 2020;21(1):265.

Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44(8):1044-1052.

Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41(1):46-52.

Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-Centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4(9):699-707.

Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223-1232.

Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67(12):1572-1579.

Straumann A, Hoesli S, Ch B, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013;68(3):375-385.

Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Repir Med. 2021;9(1):43-56.

Legrand F, Cao Y, Wechsler JB, et al. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: receptor expression and targeting using chimeric antibodies. J Allergy Clin Immunol. 2019;143(6):2227-2237.

Accessed August 13, 2023. https://investor.allakos.com/news-releases/news-release-details/allakos-announces-topline-phase-3-data-enigma-2-study-and-phase/

Rasmussen HS, Chang AT, Tomasevic N, Bebbington C. Phase 1 double-blind, placebo-controlled, ascending dose study of Siglec-8 selective mAb AK002 in healthy subjects. J Allergy Clin Immunol. 2018;141(2):AB403.

Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018;132(5):501-509.

Laidlaw TM, Prussin C, Panettieri RA, et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with not change in polyp size. Laryngoscope. 2019;129(2):E61-E66.

Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945.

Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002;169(2):1021-1027.

Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748-756.

Panettieri RA Jr, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511-525.

Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.

Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir Med. 2018;6(7):499-510.

Gutermuth J, Pink AE, Soldbro L, Bjerregard Oland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440-452.

Jesenak M, Diamant Z. Blood eosinophils: in quest of a holy grail for personalized asthma treatment with biologicals. Allergy. 2020;75(6):1294-1297.

Wood LJ, Sehmi R, Dorman S, et al. Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. Am J Respir Crit Care Med. 2002;166(6):883-889.

Johansson K, Malmhäll C, Ramos-Ramírez P, Rådinger M. Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. Immunology. 2018;153(2):268-278.

Hogan MB, Piktel D, Landreth KS. IL-5 production by bone marrow stromal cells: implications for eosinophilia associated with asthma. J Allergy Clin Immunol. 2000;106(2):329-336.

Bressler RB, Lesko J, Jones ML, et al. Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation. J Allergy Clin Immunol. 1997;99(4):508-514.

Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994;179(2):703-708.

Bhalla A, Zhao N, Rivas DD, et al. Exacerbations of severe asthma while on anti-IL-5 biologics. J Investig Allergol Clin Immunol. 2020;30(5):307-316.

Andreev D, Liu M, Kachler K, et al. Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Ann Rheum Dis. 2021;80(4):451-468.

Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628-636.

Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080-1091.

Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77:1786-1796.

Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:1299-1312.

Dorey-Stein ZL, Shenoy KV. Tezepelumab as an emerging therapeutic option for the treatment of severe asthma: evidence to date. Drug Des Devel Ther. 2021;15:331-338.

Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021;59:2101296.

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)